NCT00044187已完成4 期
The Assessment of a Anti-Obesity Agent for the Treatment of Olanzapine-Associated Weight Gain in Patients With Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder and Bipolar I Disorder
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 130
- 试验地点
- 16
研究概览
简要总结
Olanzapine is currently marketed for the treatment of schizophrenia and acute manic episodes with bipolar 1 disorder. This Anti-obesity Agent is currently marketed for the management of obesity. In this study, the Anti-obesity Agent is being tested to see if it can treat weight gain that may be associated with taking olanzapine.
The purposes of this study are to determine the safety of olanzapine when given in combination with the Anti-obesity Agent and any side effects that might be associated with it and whether weight-gain agent can help treat weight gain that may be associated with taking olanzapine.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- •You have a history of an illness that would cause weight loss or gain in the near future.
- •You have taken remoxipride within the past 6 months.
- •You are allergic to olanzapine or Anti-obesity Agent.
- •You have uncontrolled high blood pressure, congestive heart failure, or have had a stroke.
- •You have a serious medical illness, such as heart, liver, or kidney disease.
- •You are pregnant or breast feeding.
研究者
研究点 (16)
Loading locations...
相似试验
已完成
4 期
Comparing the Effect of Under the Tongue Olanzapine Versus Swallowed Olanzapine on Body Mass Index (A Ratio of Weight to Height)SchizophreniaBipolar DisorderSchizoaffective DisorderNCT00303602Eli Lilly and Company149
已完成
4 期
A Study on Induced Weight Gain During Atypical Antipsychotic Treatment and Its Management With Psychoeducational ProgrammeWeight GainNCT00191828Eli Lilly and Company60
已完成
2 期
Olanzapine in the Treatment of Patients With Anorexia NervosaAnorexia NervosaNCT00260962Ottawa Hospital Research Institute34
Unknown
2 期
Acute Olanzapine and Lipid ResponseHealthyNCT04181385University Health Network, Toronto15
终止
不适用
Aggressive Treatment of Metabolic Syndrome in Patients Receiving Clozapine for SchizophreniaMetabolic SyndromeNCT00794963Northwell Health8